Please ensure Javascript is enabled for purposes of website accessibility

Thermo Fisher to Turn Coronavirus Antibody Testing on Its Head

By Cory Renauer - Updated May 13, 2020 at 4:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its new test that will detect two types of SARS-CoV-2 antibodies will run on an open instrument platform.

Thermo Fisher Scientific (TMO -0.58%) is expanding its response to the coronavirus pandemic with a little help from some friends. The Mayo Clinic and WuXi Diagnostics will collaborate with it on the development of the Thermo Fisher Scientific OmniPath COVID-19 Total Antibody ELISA test.

Something different 

New antibody tests from AbbottQuest Diagnostics, and some of their peers have already been given emergency use authorization (EUA) by the FDA. These look for relatively simple immunoglobulin G (IgG) antibodies that our immune systems produce in response to SARS-CoV-2. The new test from Thermo Fisher and its collaboration partners will also detect complex immunoglobulin M (IgM) antibodies that appear in the early stage of the immune response.

Coronavirus sample tube

Image source: Getty Images.

Thermo Fisher also intends for its new SARS-CoV-2 antibody test to be processed on an open instrument platform. That should mean healthcare providers with the capacity to run other antibody tests will also be able to process this one.

Next steps

Thermo Fisher says it will start manufacturing its new SARS-CoV-2 antibody test in the U.S. and EU over the next few weeks. WuXi Diagnostics will assist with its international development, and (assuming the test gets authorized for emergency use, as is widely expected) will also assist with manufacturing and commercialization.

The Mayo Clinic won't be much help on the manufacturing front, but it will still play a role. The clinical experience of its physicians and the laboratory experience of its scientists could help Thermo Fisher's new antibody test quickly become one of the more popular COVID-19 diagnostics.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$545.07 (-0.58%) $-3.20
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$109.30 (-0.83%) $0.92
Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$133.58 (-2.27%) $-3.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.